Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $3.02 in the prior trading day, Poseida Therapeutics Inc (NASDAQ: PSTX) closed at $3.13, up 3.64%. In other words, the price has increased by $3.64 from its previous closing price. On the day, 0.55 million shares were traded. PSTX stock price reached its highest trading level at $3.38 during the session, while it also had its lowest trading level at $3.08.
Ratios:
Our goal is to gain a better understanding of PSTX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1445.17. For the most recent quarter (mrq), Quick Ratio is recorded 2.48 and its Current Ratio is at 2.48. In the meantime, Its Debt-to-Equity ratio is 1.38 whereas as Long-Term Debt/Eq ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 04, 2023, initiated with a Buy rating and assigned the stock a target price of $15.
On January 07, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $24.
On May 18, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $40.BTIG Research initiated its Buy rating on May 18, 2021, with a $40 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PSTX now has a Market Capitalization of 303986240 and an Enterprise Value of 149827152. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.43 while its Price-to-Book (P/B) ratio in mrq is 5.00. Its current Enterprise Value per Revenue stands at 1.694 whereas that against EBITDA is -1.328.
Stock Price History:
The Beta on a monthly basis for PSTX is 0.58, which has changed by 0.14652014 over the last 52 weeks, in comparison to a change of 0.17286706 over the same period for the S&P500. Over the past 52 weeks, PSTX has reached a high of $4.27, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is 2.76%, while the 200-Day Moving Average is calculated to be 5.57%.
Shares Statistics:
The stock has traded on average 458.26K shares per day over the past 3-months and 599530 shares per day over the last 10 days, according to various share statistics. A total of 95.64M shares are outstanding, with a floating share count of 63.58M. Insiders hold about 34.43% of the company’s shares, while institutions hold 49.89% stake in the company. Shares short for PSTX as of 1721001600 were 5215939 with a Short Ratio of 11.38, compared to 1718323200 on 4539591. Therefore, it implies a Short% of Shares Outstanding of 5215939 and a Short% of Float of 7.4499995.
Earnings Estimates
The dynamic stock of Poseida Therapeutics Inc (PSTX) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.28 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.18 and -$1.71 for the fiscal current year, implying an average EPS of -$1.44. EPS for the following year is -$1.79, with 4.0 analysts recommending between -$1.27 and -$2.54.
Revenue Estimates
3 analysts predict $15.43M in revenue for the current quarter. It ranges from a high estimate of $18.8M to a low estimate of $12.5M. As of the current estimate, Poseida Therapeutics Inc’s year-ago sales were $9.35MFor the next quarter, 3 analysts are estimating revenue of $15.43M. There is a high estimate of $18.8M for the next quarter, whereas the lowest estimate is $12.5M.
A total of 3 analysts have provided revenue estimates for PSTX’s current fiscal year. The highest revenue estimate was $84.4M, while the lowest revenue estimate was $65.6M, resulting in an average revenue estimate of $74.38M. In the same quarter a year ago, actual revenue was $64.7MBased on 3 analysts’ estimates, the company’s revenue will be $38.33M in the next fiscal year. The high estimate is $70M and the low estimate is $10M.
